Analytical Data
-
Gene name
HLA-A*02:01&B2M&GP100(YLEPGPVTA) Monomer
- Application
-
Alternative Names
HLA0201; MHC I; gp100; Glycoprotein 100; ME20-M; P100
-
Species
Human
-
Source
HEK293
-
Tag
C-Avi;C-8*His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
A0A140T913 (G25-T305)&P61769
-
Expression Region
A0A140T913 (G25-T305)&P61769 (I21-M119)&YLEPGPVTA
-
Molecular Weight
52-62 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The HLA-A*02:01 molecule, a major histocompatibility complex (MHC) class I antigen, plays a crucial role in the immune response by presenting peptide antigens to CD8+ T cells, thereby facilitating the recognition and elimination of infected or malignant cells. The B2M (beta-2-microglobulin) component is essential for the stability and proper assembly of the HLA class I complex. GP100, a melanoma-associated antigen, is particularly significant as it is recognized by T cells in melanoma patients, with the peptide YLEPGPVTA being a well-studied epitope presented by HLA-A*02:01. Research on the recombinant monomer of HLA-A*02:01 in complex with B2M and the gp100-derived peptide YLEPGPVTA aims to enhance our understanding of T cell recognition and activation mechanisms in the context of melanoma immunotherapy. By studying this monomeric complex, researchers hope to elucidate the molecular interactions involved in T cell activation and to potentially identify novel therapeutic targets or strategies to improve patient responses to immune checkpoint inhibitors or peptide-based vaccines. This research is particularly timely, given the increasing focus on personalized medicine and the need for effective approaches to harness the immune system against cancer.
